Oraya® Therapeutics, Inc. announced today that initial three-year safety follow-up data from its INTREPID study of Oraya Therapy™ stereotactic radiotherapy for the treatment of wet age-related macular degeneration (AMD) were presented for the first time today during the America Academy of Ophthalmology’s (AAO) annual meeting in New Orleans.
Oraya Therapeutics, Inc. and OnCore Manufacturing LLC announced today the production of the first commercial unit in the United States of the IRay® Radiotherapy System for the treatment of wet age-related macular degeneration (AMD)
For a limited time and while supplies last, Oraya is offering interested physicians a free copy of the INTREPID Study Results published in Ophthalmology, September 2013.
Oraya Therapeutics, Inc. announced today the two-year results of its INTREPID study of Oraya Therapy™ Stereotactic Radiotherapy for the treatment of wet age-related macular degeneration (AMD)
The publication of key Oraya Therapy presentations from the 12th EURETINA Congress is now available.
The Oraya Therapy is now available at Optegra Manchester Eye Hospital. Interested parties in the United Kingdom, please call 0800 358 0825 or click here for more information.
Other locations offering the Oraya Therapy include Optegra Eye Hospital, Guildford and Basel Vista Klinik, Switzerland. For more information about Oraya Therapy Centers for Excellence, visit our Treatment Locations page.
Oraya prepares for European rollout of IRay for wet AMD. Oraya Therapeutics (Newark, California), along with its manufacturing partner OnCore Manufacturing (Fremont, California), has produced the first commercial unit in the U.S. of the IRay radiation system for wet AMD… Download Full Article
East Bay connection: Oraya, OnCore partnership a lesson in medical manufacturing. Oraya Therapeutics doesn’t expect to sell millions of its treatment for the blinding eye disease known as wet age-related macular degeneration. Yet as the Newark company starts selling its system in Europe…Read More
Healthcare startup with noninvasive, one-time wet AMD treatments touts two years of success. Oraya Therapeutics, one of California’s many healthcare startups, has distinguished itself from the crowd. The medical device company recently presented results from a two-year study…Read More
Two-year results of Oraya Therapeutics’ INTREPID study are presented, showing the radiation therapy for wet AMD is safe and effective. Click here or below to access the online news feature.
The first person in the world to have a revolutionary radiotherapy treatment in both eyes is delighted with the resultant improvement in her vision and reduction in anti-VEGF injections. Download a Copy of Stella’s Story.
One of the first wet AMD patients in the world treated with a single 20-minute radiotherapy treatment has had improved vision and no subsequent anti-VEGF injections for two years. Download a copy of Jonny’s story or watch the video below.
To discuss the exciting potential of Oraya Therapy to significantly reduce the burden of care for wet AMD treatment, a panel of retinal
experts and clinicians shared their experience of this ground-breaking technology at a special EuroTimes Satellite Education symposium
held during the 12th EURETINA Congress in Milan in September 2012. Click here or below to access the online video presentations.